Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Single and Multiple-dose, Study to Evaluate Safety, Tolerability and Efficacy of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Squamous Intraepithelial Lesions

NCT05502367 is registered in ClinicalTrials.gov with Antiva Biosciences as lead sponsor.

NCT NCT05502367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05502367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Single and Multiple-dose, Study to Evaluate Safety, Tolerability and Efficacy of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Squamous Intraepithelial Lesions
Lead sponsor
Antiva Biosciences
Phase
Phase 1/2
Overall status
Terminated
Start date
September 10, 2022
Completion date
October 27, 2025
Enrollment
44 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia